COMMUNIQUÉS West-GlobeNewswire

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
07/11/2024
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. [...]
Kura Oncology Reports Third Quarter 2024 Financial Results
07/11/2024
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation [...]
PacBio Announces Third Quarter 2024 Financial Results
07/11/2024
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
07/11/2024
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/ [...]
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance
07/11/2024
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024
07/11/2024
Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectively Received $122 Million of Procurement Orders from the U.S. Government in the Third Quarter Corporate [...]
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
07/11/2024
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First [...]
Rani Therapeutics to Participate in Upcoming Investor Conferences
07/11/2024
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
07/11/2024
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meeting Han Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial [...]
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
06/11/2024
PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced [...]
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
06/11/2024
Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp . (Nasdaq: OCX), a diagnostics technology company, announced [...]
Viemed Healthcare Announces Third Quarter 2024 Financial Results
06/11/2024
LAFAYETTE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced [...]
Monthly information on share capital and company voting rights
06/11/2024
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/11/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 nov. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®
06/11/2024
LOUISVILLE, Ky., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a BrightSpring company and leading independent [...]
Surrozen to Present at Upcoming Healthcare Investor Conferences
06/11/2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue [...]
DBV Technologies Reports Third Quarter 2024 Financial Results
06/11/2024
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN [...]
DBV Technologies publie ses résultats financiers du troisième trimestre 2024
06/11/2024
Châtillon, France, le 6 novembre (22 :30 CET) 2024 DBV Technologies publie ses résultats financiers du troisième trimestre 2024 DBV clôture le troisième trimestre 2024 avec un solde de trésorerie de 46,4 $ millions [...]
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
06/11/2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]

Pages